NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Elixiron Immunotherapeutics

Elixiron Immunotherapeutics

Public

Last Round

Series B

Jun 12, 2025

Total Funding Raised

$70M

Company Overview

Elixiron Immunotherapeutics is a clinical-stage biotechnology company that develops precision immunotherapies for neuroinflammatory diseases, autoimmune diseases, and cancer.

AI Layer

Application

Keywords

immunotherapydrug discoverytherapeutic vaccinemonoclonal antibodybiotechoncologyinflammatory diseaseai drug discoveryclinical-stage biotechbiopharmaprecision medicinedrug licensingin silico drug designmulti-omics

Elixiron Immunotherapeutics Comps

Public and private peers based on sector, stage, and business model.

Elixiron Immunotherapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Elixiron Immunotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 12, 2025
GrantJul 12, 2022
Series A ExtensionAug 23, 2021
GrantAug 25, 2020
Series AJul 31, 2019

Key People

Founding team and executive leadership

Cheng-Lung KU

Chief Science Officer, Co-Founder

Founding Team

Elixiron Immunotherapeutics Investors

Notable investors and investment history

Elixiron Immunotherapeutics investors
InvestorRounds
Taiwania CapitalSeries A, Series A Extension
Fubon Financial Holding Venture CapitalSeries A Extension
CDIB Capital InternationalSeries A
China Investment & Development Company, LimitedSeries A Extension
Alzheimer's AssociationGrant
Fubon Financial HoldingsSeries A Extension

Elixiron Immunotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Elixiron Immunotherapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

Headquarters
Employee Range23
Year Founded2017
Last FundingJun 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.